Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia von Flynn, J, Jones, J, Johnson, A J, Andritsos, L, Maddocks, K, Jaglowski, S, Hessler, J, Grever, M R, Im, E, Zhou, H, Zhu, Y, Zhang, D, Small, K, Bannerji, R, Byrd, J C

Volltext

The novel cyclin-dependent kinase inhibitor dinaciclib (SCH727965) promotes apoptosis and abrogates microenvironmental cytokine protection in chronic lymphocytic leukemia cells von Johnson, A J, Yeh, Y-Y, Smith, L L, Wagner, A J, Hessler, J, Gupta, S, Flynn, J, Jones, J, Zhang, X, Bannerji, R, Grever, M R, Byrd, J C

Volltext

Flavaglines target primitive leukemia cells and enhance anti-leukemia drug activity von Callahan, K P, Minhajuddin, M, Corbett, C, Lagadinou, E D, Rossi, R M, Grose, V, Balys, M M, Pan, L, Jacob, S, Frontier, A, Grever, M R, Lucas, D M, Kinghorn, A D, Liesveld, J L, Becker, M W, Jordan, C T

Volltext

Outcome of patients with relapsed or refractory chronic lymphocytic leukemia treated with flavopiridol: impact of genetic features von Woyach, J A, Lozanski, G, Ruppert, A S, Lozanski, A, Blum, K A, Jones, J A, Flynn, J M, Johnson, A J, Grever, M R, Heerema, N A, Byrd, J C

Volltext

Risk factors for tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridol von Blum, K A, Ruppert, A S, Woyach, J A, Jones, J A, Andritsos, L, Flynn, J M, Rovin, B, Villalona-Calero, M, Ji, J, Phelps, M, Johnson, A J, Grever, M R, Byrd, J C

Volltext

Impact of targeted therapy on outcome of chronic lymphocytic leukemia patients with relapsed del(17p13.1) karyotype at a single center von Stephens, D M, Ruppert, A S, Jones, J A, Woyach, J, Maddocks, K, Jaglowski, S M, Andritsos, L A, Flynn, J M, Grever, M R, Lozanski, G, Johnson, A J, Muthusamy, N, Heerema, N A, Byrd, J C

Volltext

Mitochondrial priming of chronic lymphocytic leukemia patients associates Bcl-[x.sub.L] dependence with alvocidib response von Pierceall, W.E, Warner, S.L, Lena, R.J, Doykan, C, Blake, N, Elashoff, M, Hoff, D.V, Bearss, D.J, Cardone, M.H, Andritsos, L, Byrd, J.C, Lanasa, M.C, Grever, M.R, Johnson, A.J

Volltext

A Phase I Study of GTI-2040, an Antisense to Ribonucleotide Reductase (RNR) in Combination with High-Dose Cytarabine (HiDAC) in Relapsed or Refractory Acute Myeloid Leukemia (AML):... von Klisovic, Rebecca B., Blum, W., Wei, X., Liu, S., Kefauver, C., Huynh, L., Zwiebel, J.A., Byrd, J.C., Grever, M.R., Marcucci, G.

Volltext

Methylation of the Tumor Suppressor Gene PTPRO (Receptor-Type Protein Tyrosine Phosphatase) Is Associated with Expression of Important Apoptosis-Related Proteins in Chronic Lymphoc... von Motiwala, T., Ghoshal, K., Majumder, S., Kutay, H., Neuberg, D.S., Kitada, S., Reed, J.C., Dewald, G.W., Flinn, I.W., Tallman, M.A., Liu, T., Plass, C., Lucas, D.M., Byrd, J.C., Jacob, S.T., Grever, M.R.

Volltext

Intracellular Levels of Oblimersen Sodium and Target Downregulation Correlates to Clinical Activity of bcl-2 Antisense in Acute Myeoid Leukemia (AML) von Marcucci, Guido, Stock, W., Dai, G., Liu, S., Klisovic, R., Klisovic, M.I., Sher, D., Huynh, L., Frankel, S., Blum, W., Larson, R.A., Grever, M.R., Byrd, J.C., Chan, K.K.

Volltext

National Cooperative Natural Products Drug Discovery Group (NCNPDDG) and International Cooperative Biodiversity Group (ICBG) programs von Suffness, M, Cragg, G.M, Grever, M.R, Grifo, F.J, Johnson, G, Mead, J.A.R, Schepartz, S.A, Venditti, J.M, Wolpert, M

Volltext

The interactions between biogenic amines and pyridoxal, pyridoxal phosphate, and pyridoxal kinase von Neary, J.T., Meneely, R.L., Grever, M.R., Diven, W.F.

Volltext